Nerve Growth Factor (Ngf) Responsive Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Nerve Growth Factor (NGF) Responsive Neurons are neurons that express the TrkA (Tropomyosin receptor kinase A) receptor and respond to NGF signaling. These neurons are critical for neuronal survival, differentiation, and maintenance throughout the lifespan.
NGF-responsive neurons are primarily found in:
- Peripheral nervous system: Sensory neurons, sympathetic neurons
- Central nervous system: Basal forebrain cholinergic neurons, specific cortical and hippocampal populations
- Basal forebrain (nucleus basalis of Meynert)
- Hippocampal formation
- Dorsal root ganglia
- Sympathetic ganglia
- NGF binds to TrkA receptor (high affinity)
- Receptor dimerization and autophosphorylation
- Activation of downstream signaling cascades:
- PI3K/Akt pathway: Promotes cell survival
- Ras/MAPK pathway: Regulates differentiation
- PLCγ pathway: Modulates calcium signaling
- TrkA (NTRK1): High-affinity NGF receptor
- p75NTRN (TNFRSF21): Low-affinity co-receptor
- Sortilin (SORT1): Co-receptor for p75NTR signaling
NGF-responsive neurons exhibit:
- Resting membrane potential: -60 to -70 mV
- Action potential duration: 1-2 ms
- Synaptic plasticity: LTP and LTD capability
- Calcium dynamics: NGF modulates calcium homeostasis
- Basal forebrain cholinergic neurons are NGF-responsive and degenerate early in AD
- NGF signaling impairment contributes to cholinergic atrophy
- Therapeutic strategies: NGF gene therapy, NGF mimetics
- NGF may protect dopaminergic neurons
- Reduced NGF levels in PD brains
- Experimental NGF treatments in animal models
- Diabetic neuropathy involves NGF deficiency
- NGF therapy in clinical trials for small fiber neuropathy
- Hereditary sensory and autonomic neuropathies
- Recombinant NGF protein: Limited by blood-brain barrier
- Gene therapy: AAV-NGF delivery to basal forebrain
- Small molecule TrkA agonists: Blood-brain barrier permeable
- NGF mimetics: Peptide agonists
- Phase I/II trials for NGF in Alzheimer's disease
- Gene therapy approaches (CERE-110)
- Combination with cholinesterase inhibitors
- TrkA immunohistochemistry
- NGF level ELISA
- qPCR for NGF and TrkA expression
- Western blot analysis
- TrkA knockout mice
- NGF-overexpressing transgenic mice
- iPSC-derived NGF-responsive neurons
- 5xFAD/NGF combination models
The study of Nerve Growth Factor (Ngf) Responsive Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Aloe L, et al. (2012). NGF and neurodegeneration: Lessons from the olfactory system. Frontiers in Neuroanatomy.
- Capsoni S, et al. (2016). Alzheimer disease and NGF therapy. Aging Clinical and Experimental Research.
- Cattaneo A, et al. (2019). NGF and AD: The long journey to clinical translation. Journal of Alzheimer's Disease.
- Demessino L, et al. (2021). TrkA agonists as disease-modifying therapies for Alzheimer's. Neurobiology of Disease.
- Miller S, et al. (2020). NGF gene therapy for neurodegenerative diseases. Molecular Therapy.
- Ocrava J, et al. (2018). Basal forebrain NGF signaling in AD. Nature Reviews Neurology.
- Ruberti F, et al. (2019). NGF delivery strategies for CNS disorders. Pharmaceuticals.
- Tuszynski MH, et al. (2005). Nerve growth factor gene therapy for Alzheimer's disease. Nature Medicine.